215 related articles for article (PubMed ID: 31127087)
21. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
22. Self-targeted knockdown of CD44 improves cisplatin sensitivity of chemoresistant non-small cell lung cancer cells.
Quan YH; Lim JY; Choi BH; Choi Y; Choi YH; Park JH; Kim HK
Cancer Chemother Pharmacol; 2019 Mar; 83(3):399-410. PubMed ID: 30515553
[TBL] [Abstract][Full Text] [Related]
23. Aza-PBHA, a potent histone deacetylase inhibitor, inhibits human gastric-cancer cell migration via PKCα-mediated AHR-HDAC interactions.
Tsai CH; Li CH; Liao PL; Chang YW; Cheng YW; Kang JJ
Biochim Biophys Acta Mol Cell Res; 2020 Feb; 1867(2):118564. PubMed ID: 31672612
[TBL] [Abstract][Full Text] [Related]
24. Cytoplasmic RAP1 mediates cisplatin resistance of non-small cell lung cancer.
Xiao L; Lan X; Shi X; Zhao K; Wang D; Wang X; Li F; Huang H; Liu J
Cell Death Dis; 2017 May; 8(5):e2803. PubMed ID: 28518145
[TBL] [Abstract][Full Text] [Related]
25. KiSS-1 Modulation by Epigenetic Agents Improves the Cisplatin Sensitivity of Lung Cancer Cells.
Beretta GL; Alampi D; Corno C; Carenini N; Corna E; Perego P
Int J Mol Sci; 2024 May; 25(9):. PubMed ID: 38732265
[TBL] [Abstract][Full Text] [Related]
26. The HDAC inhibitor GCJ-490A suppresses c-Met expression through IKKα and overcomes gefitinib resistance in non-small cell lung cancer.
He T; Gao Y; Fang Y; Zhang Y; Zhang S; Nan F; Ding J; Chen Y
Cancer Biol Med; 2022 Feb; 19(8):1172-92. PubMed ID: 35188360
[TBL] [Abstract][Full Text] [Related]
27. Human RECQL5 promotes metastasis and resistance to cisplatin in non-small cell lung cancer.
Xia HW; Zhang ZQ; Yuan J; Niu QL
Life Sci; 2021 Jan; 265():118768. PubMed ID: 33217443
[TBL] [Abstract][Full Text] [Related]
28. Downregulation of HIF-2α Reverse the Chemotherapy Resistance of Lung Adenocarcinoma A549 Cells to Cisplatin.
Gao ZJ; Yuan WD; Yuan JQ; Yuan K; Wang Y
Med Sci Monit; 2018 Feb; 24():1104-1111. PubMed ID: 29469087
[TBL] [Abstract][Full Text] [Related]
29. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
Gao J; Meng Q; Zhao Y; Chen X; Cai L
BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
[TBL] [Abstract][Full Text] [Related]
30. HDAC/MIF dual inhibitor inhibits NSCLC cell survival and proliferation by blocking the AKT pathway.
Cao F; Xiao Z; Chen S; Zhao C; Chen D; Haisma HJ; Dekker FJ
Bioorg Chem; 2021 Dec; 117():105396. PubMed ID: 34649152
[TBL] [Abstract][Full Text] [Related]
31. The PAX6-ZEB2 axis promotes metastasis and cisplatin resistance in non-small cell lung cancer through PI3K/AKT signaling.
Wu DM; Zhang T; Liu YB; Deng SH; Han R; Liu T; Li J; Xu Y
Cell Death Dis; 2019 Apr; 10(5):349. PubMed ID: 31024010
[TBL] [Abstract][Full Text] [Related]
32. Novel alkoxyamide-based histone deacetylase inhibitors reverse cisplatin resistance in chemoresistant cancer cells.
Asfaha Y; Schrenk C; Alves Avelar LA; Lange F; Wang C; Bandolik JJ; Hamacher A; Kassack MU; Kurz T
Bioorg Med Chem; 2020 Jan; 28(1):115108. PubMed ID: 31787463
[TBL] [Abstract][Full Text] [Related]
33. MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer.
Chattopadhyay S; Machado-Pinilla R; Manguan-García C; Belda-Iniesta C; Moratilla C; Cejas P; Fresno-Vara JA; de Castro-Carpeño J; Casado E; Nistal M; Gonzalez-Barón M; Perona R
Oncogene; 2006 Jun; 25(23):3335-45. PubMed ID: 16462770
[TBL] [Abstract][Full Text] [Related]
34. Simultaneous targeting of ATM and Mcl-1 increases cisplatin sensitivity of cisplatin-resistant non-small cell lung cancer.
Zhang F; Shen M; Yang L; Yang X; Tsai Y; Keng PC; Chen Y; Lee SO; Chen Y
Cancer Biol Ther; 2017 Aug; 18(8):606-615. PubMed ID: 28686074
[TBL] [Abstract][Full Text] [Related]
35. CHD1L contributes to cisplatin resistance by upregulating the ABCB1-NF-κB axis in human non-small-cell lung cancer.
Li Y; He LR; Gao Y; Zhou NN; Liu Y; Zhou XK; Liu JF; Guan XY; Ma NF; Xie D
Cell Death Dis; 2019 Feb; 10(2):99. PubMed ID: 30718500
[TBL] [Abstract][Full Text] [Related]
36. SNHG14 silencing suppresses the progression and promotes cisplatin sensitivity in non-small cell lung cancer.
Jiao P; Hou J; Yao M; Wu J; Ren G
Biomed Pharmacother; 2019 Sep; 117():109164. PubMed ID: 31252267
[TBL] [Abstract][Full Text] [Related]
37. siRNA silencing EZH2 reverses cisplatin-resistance of human non-small cell lung and gastric cancer cells.
Zhou W; Wang J; Man WY; Zhang QW; Xu WG
Asian Pac J Cancer Prev; 2015; 16(6):2425-30. PubMed ID: 25824776
[TBL] [Abstract][Full Text] [Related]
38. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.
Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q
Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681
[TBL] [Abstract][Full Text] [Related]
39. Elevation of FGD5-AS1 contributes to cell progression by improving cisplatin resistance against non-small cell lung cancer cells through regulating miR-140-5p/WEE1 axis.
Fu J; Cai H; Wu Y; Fang S; Wang D
Gene; 2020 Sep; 755():144886. PubMed ID: 32534055
[TBL] [Abstract][Full Text] [Related]
40. Proteomic analysis identified DJ-1 as a cisplatin resistant marker in non-small cell lung cancer.
Zeng HZ; Qu YQ; Zhang WJ; Xiu B; Deng AM; Liang AB
Int J Mol Sci; 2011; 12(6):3489-99. PubMed ID: 21747690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
